To date, EnzySurge has raised a total
EnzySurge recently received clearance from FDA to market SilverStream, its unique ionic silver wound management solution for professional use. FDA also cleared DermaSept, an Over-the-Counter version of SilverStream for management of burns, cuts and abrasions.
A single patient use disposable system, the DermaStream product line allows for the continuous streaming of fresh therapeutic solutions, such as the SilverStream solution, enzymatic debridement solutions and cleansing solutions, over the wound bed. The treatment provides constant removal of foreign material, exudate, micro-organisms and debris while creating negative pressure over the wound.
"I'm very excited with this successful private equity round of Funding,"
According to Mr. Shiner, the company operates its marketing and sales
activities from its US office in
About EnzySurge Ltd.
EnzySurge Ltd. is a developer and provider of innovative solutions for the treatment and management of chronic wounds. EnzySurge's DermaStream(R) platform offers a new and unique wound treatment modality by continuously streaming a fresh supply of advanced therapeutic solutions to a controlled wound environment. DermaStream is designed to deliver effective, affordable and easy-to-use wound treatment throughout all phases of chronic wound treatment from debridement, through regeneration to wound closure. The EnzySurge product line is intended for use in hospitals, clinics and for home care.
http://www.dermastream.com Contact Details : Amir Shiner CEO Mobile : +972-54-3030294 Eli Gilboa CHAIRMAN (Private Placement Manager) Mobile : +972-54-4570011
SOURCE EnzySurge Ltd